This trial will see if a new drug, GSK3511294, is non-inferior to current treatments for severe asthma with an eosinophilic phenotype. All participants will continue their standard of care asthma treatment.
1 Primary · 3 Secondary · Reporting Duration: Baseline (Day 1) and up to Week 52
Active Control
Experimental Treatment
1700 Total Participants · 2 Treatment Groups
Primary Treatment: GSK3511294 (Depemokimab) · Has Placebo Group · Phase 3
Age Any Age · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Nebraska | 25.0% |
Kansas | 25.0% |
California | 25.0% |
Other | 25.0% |
18 - 65 | 100.0% |
GSK Investigational Site | 100.0% |
Did not meet criteria | 75.0% |
Met criteria | 25.0% |